There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and ...

According to DelveInsight's analysis, the market for GIST is anticipated to increase during the forecast period (2025–2034), owing to the launch of e ...

An estimated 18,000 people in the United States annually suffer from new injuries to their spinal cords. Unfortunately for ...

The global Osimertinib drugs market is on the verge of significant expansion, with an estimated rise in revenue from US$ 4,828.6 million in 2021 to US$ 11,829.8 million by 2027. This growth reflects a ...

The FDA converts its accelerated approval to full approval for BAYRY's oncology drug, Vitrakvi, on positive data from ...

Bayer’s Vitrakvi (larotrectinib) has been granted traditional approval by the US Food and Drug Administration (FDA) to treat ...

Cogent Biosciences, Inc.’s COGT share price has dipped by 11.10%, which has investors questioning if this is right time to ...

The U.S. Food And Drug Administration (FDA) granted full approval to Bayer AG’s (OTC:BAYRY) Vitrakvi (larotrectinib) for ...

Patients with chronic lymphocytic leukemia (CLL) who experience Richter transformation have a poor prognosis, but ibrutinib ...

The U.S. Food and Drug Administration (FDA) has granted full approval to Vitrakvi (larotrectinib) for the treatment of adult ...

U.S. FDA Grants Full Approval of VITRAKVI® (larotrectinib) for Adult and Pediatric Patients with NTRK Gene Fusion-Positive ...